Back

Real-world treatments and outcomes in very old patients with heart failure with preserved ejection fraction

29 August 2025 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: HFpEF progress Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Olivier Hanon

Hospital Broca of Paris, Paris (France)

6 More presentations in this session

Presentation thumbnail
Prognostic value of the combination of marasmus and kwashiorkor in patients admitted for acute decompensated heart failure with preserved ejection fraction
Doctor R. Yagi (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Multicellular trajectories leading to subclinical diastolic dysfunction and HFpEF progression in cardiometabolic comorbidities.
Miss A. Ausiello (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
An alternative clinical score for the diagnosis of heart failure with preserved left ventricular ejection fraction in patients with atrial fibrillation
Doctor A. Sevcik (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Plasma proteomic profiles of left ventricular diastolic dysfunction differ by sex in a population at risk for cardiovascular disease
Doctor E. Dal Canto (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved ejection fraction - A meta-analysis of randomised-controlled trials
Doctor R. Ravikulan (Adelaide, AU)
Abstract Slides Video

Access the full session

Session thumbnail
HFpEF progress

The Event

Event poster

ESC Congress 2025

29 August 2025 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of SGLT2 inhibitors in heart failure: real-world evidence in geriatric patients
thumbnail
Congress Presentation
Real-world treatments and outcomes in very old patients with heart failure with preserved ejection fraction
thumbnail
Congress Presentation
Efficacy and safety of SGLT2 inhibitors in heart failure: observational evidence in geriatric patients AGING-HF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources